Clinical Trial Update: Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes FRF-001, an AAV-9 gene therapy intended to treat FOXG1 Syndrome. The study is in Phase 1/2 but not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Foxg1 Syndrome

Drugs mentioned

• FRF-001

Snippet

Sponsor: FOXG1 Research Foundation | Conditions: FOXG1 Syndrome | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING